| Catalog No. | HV255056 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | IgG4-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | CD85 antigen-like family member D, Monocyte/macrophage immunoglobulin-like receptor 10, MIR-10, ILT4, LIR-2, ILT-4, Immunoglobulin-like transcript 4, MIR10, CD85d, Leukocyte immunoglobulin-like receptor subfamily B member 2, Leukocyte immunoglobulin-like receptor 2, LIR2, LILRB2 |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q8N423 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -1401°C. |
|---|
| Alternate Names | CAS:2640981-19-5 |
|---|
| Background | Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
